Postconditioning with curaglutide, a novel GLP-1 analog, protects against heart ischemia-reperfusion injury in an isolated rat heart

Regulatory Peptides

Volumn 178, Issue 1-3, 2012, Pages 51-55

  Salling, Henrik K ^a   Döhler, Klaus D ^b   Engstrøm, Thomas ^c   Treiman, Marek ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b IPF PHARMACEUTICALS GMBH   (Germany)

^c Rigshospitalet   (Denmark)

Author keywords

Curaglutide; GLP 1; Ischemia reperfusion injury; Myocardial infarction; Postconditioning

Indexed keywords

CURAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG MECHANISM; EX VIVO STUDY; HEART BEAT; HEART INFARCTION SIZE; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE ISCHEMIA; HEART PROTECTION; ISCHEMIC POSTCONDITIONING; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REPERFUSION INJURY;

ANIMALS; AREA UNDER CURVE; CARDIOTONIC AGENTS; CORONARY VESSELS; GLUCAGON-LIKE PEPTIDE 1; MALE; MYOCARDIAL REPERFUSION INJURY; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, GLUCAGON; VENTRICULAR PRESSURE;

RATTUS;

EID: 84865349041     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2012.06.007     Document Type: Article

References (32)

1. Yellon D.M., Hausenloy D.J. Myocardial reperfusion injury. N Engl J Med 2007, 357:1121-1135.
2. Turer A.T., Hill J.A. Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol 2010, 106:360-368.
3. Miura T., Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol 2008, 103:501-513.
4. Hellermann J.P., Jacobsen S.J., Redfield M.M., et al. Heart failure after myocardial infarction: clinical presentation and survival. Eur J Heart Fail 2005, 7:119-125.
5. Ovize M., Baxter G.F., Di Lisa F., et al. Postconditioning and protection from reperfusion injury: where do we stand? Position paper from the working group of cellular biology of the heart of the European Society of Cardiology. Cardiovasc Res 2010, 87:406-423.
6. Hausenloy D.J., Yellon D.M. The therapeutic potential of ischemic conditioning: an update. Nat Rev Cardiol 2011, 8:619-629.
7. Bose A.K., Mocanu M.M., Carr R.D., Brand C.L., Yellon D.M. Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury. Diabetes 2005, 54:146-151.
8. Treiman M., Elvekjær M., Engstrøm T., Jensen J.S. Glucagon-like peptide 1-a cardiologic dimension. Trends Cardiovasc Med 2010, 20:8-12.
9. Deacon C.F. Circulation and degradation of GIP and GLP-1. Horm Metab Res 2004, 36:761-765.
10. Estall J.L. Drucker DJ Glucagon and glucagon-like peptide receptors as drug targets. Curr Pharm Des 2006, 12:1731-1750.
11. Garber A.J. Novel GLP-1 receptor agonists for diabetes. Exp Op invest Drugs 2012, 21:45-57.
12. Noyan-Ashraf M.H., Momen M.A., Ban K., Sadi A.M., Zhou Y.Q., et al. GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice. Diabetes 2009, 58:975-983.
13. Sonne D.P., Engstrom T., Treiman M. Protective effects of GLP-1 analogues exendin-4 and GLP-1(9-36) amide against ischemia-reperfusion injury in rat heart. Regul Pept 2008, 46:243-249.
14. Timmers L., Henriques J.P.S., de Kleijn D.P.V., et al. Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury. J Am Coll Cardiol 2009, 53:501-510.
15. Ban K., Kim K.-H., Cho C.-K., Sauve M., Diamandis E.P., Backx P.H., Drucker D.J., Husain M. Glucagon-like peptide (GLP)-1(9-36)amide-mediated cytoprotection is blocked by exendin(9-39) yet does not require the known GLP-1 receptor. Endocrinology 2010, 151:1520-1531.
16. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
17. Bose A.K., Mocanu M.M., Carr R.D., Yellon D.M. Myocardial ischemia-reperfusion injury is attenuated by intact glucagon like peptide-1 (GLP-1) in the in vitro rat heart and may involve the p70s6K pathway. Cardiovasc Drugs Ther 2007, 21:253-256.
18. Bose A.K., Mocanu M.M., Carr R.D., Yellon D.M. Glucagon like peptide-1 is protective against myocardial ischemia/reperfusion injury when given either as a preconditioning mimetic or at reperfusion in an isolated rat heart model. Cradiovasc Drugs Ther 2005, 19:9-11.
19. John H., Maronde E., Forssmann W.G., Meyer M., Adermann K. N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity. Eur J Med Res 2008, 13:73-78.
20. Bell R.M., Mocanu M.M., Yellon D.M. Retrograde heart perfusion: the Langendorff technique of isolated heart perfusion. J Mol Cell Cardiol 2011, 50:940-950.
21. Goke R., Fehmann H.C., Linn T., et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993, 268:19650-19655.
22. Thorens B., Porret A., Buhler L., Deng S.P., Morel P., Widmann C. Cloning and functional expression of the human islet GLP-1 receptor. Demonstration that exendin-4 is an agonist and exendin-(9-39) an antagonist of the receptor. Diabetes 1993, 42:1678-1682.
23. Ossum A., van Deurs U., Engstrøm T., Jensen J.S., Treiman M. The cardioprotective and inotropic components of the postconditioning effects of GLP-1 and GLP-1(9-36)a in an isolated rat heart. Pharmacol Res 2009, 60:411-417.
24. Inserte J., Barrabes J.A., Hernando V., Garcia-Dorado D. Orphan targets for reperfusion injury. Cardiovasc Res 2009, 83:169-178.
25. Ladilov Y., Efe O., Schafer C., et al. Reoxygenation-induced rigor-type contracture. J Mol Cell Cardiol 2003, 35:1481-1490.
26. Doyle M.E., Egan J.M. Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol Ther 2007, 113:546-593.
27. Hausenloy D., Yellon D. Reperfusion injury salvage kinase signalling: taking a RISK for cardioprotection. Heart Fail Rev 2007, 12:217-234.
28. Ruiz-Meana M., Inserte J., Fernandez-Sanz C., Hernando V., Miro-Casa E., Barba I., Garcia-Dorado D. The role of mitochondrial permeability transition in reperfusion-induced cardiomyocyte death depends on the duration of ischemia. Basic Res Cardiol 2011, 106:1259-1268.
29. Zhao T., Parikh P., Bhashyam S., et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther 2006, 317:1106-1113.
30. Holst J.J. Pharmacology of GLP-1-based therapies. Br J Diab Vasc Dis 2008, 8:S10.
31. Lønborg J., Vejlstrup N., Kelbæk H., Bøtker H.E., et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J 2012, 33:1491-1499. [Electronic publication ahead of print].
32. Lønborg J., Kelbæk H., Vejlstrup N., Bøtker H.E., et al. Exenatide reduces final infarct size in patients with ST-segment elevation myocardial infarction and short duration of ischemia. Circ Cardiovasc Interv 2012, 5:288-295.